Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Journal of Experimental Medicine

Volumn 194, Issue 6, 2001, Pages 823-832

  Sutmuller, R P M ^a   Van Duivenvoorde, L M ^a   Van Elsas, A ^a   Schumacher, T N M ^a   Wildenberg, M E ^a   Allison, J P ^a   Toes, R E M ^a   Offringa, R ^a   Melief, C J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Depigmentation; Immunotherapy; Melanoma; Tolerance; TRP 2

Indexed keywords

CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR; MELANOMA ANTIGEN; TUMOR VACCINE; TYROSINASE RELATED PROTEIN 2;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DEPIGMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REJECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOCONJUGATES; IMMUNOTHERAPY; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035903324     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.6.823     Document Type: Article

References (40)

1. Strategies for immunotherapy of cancer
2. T-cell recognition of self peptides as tumor rejection antigens
3. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
4. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
5. CD28-DB7 interactions in T-cell activation
6. CTLA-4 can function as a negative regulator of T cell activation
7. + T cell responses
8. Molecular basis of T cell inactivation by CTLA-4
9. + effector T cells
10. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
11. + immunoregulatory T cells that control autoinmmne diabetes
12. - subpopulations
13. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells
14. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance
15. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production
16. + naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state
17. + immunoregulatory T cells is antigen nonspecific
18. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GMCSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
19. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
20. Phenotypic analysis of antigen-specific T lymphocytes
21. Systemic T cell expansion during localized viral infection
22. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody
23. The selection and characterization of an invasive variant of the B16 melanoma
24. Genetic vaccination against the melanocyte lineagespecific antigen gp100 induces cytotoxic T lymphocytemediated tumor protection
25. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
26. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
27. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes
28. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity
29. + T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration
30. T cell-mediated maintenance of natural self-tolerance: Its breakdown as a possible cause of various autoimmune diseases
31. Coupling and uncoupling of tumor immunity and autoimmunity
32. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model
33. Interleukin 2 receptors
34. The multichain interleukin-2 receptor: A target for immunotherapy
35. + T cells in the antitumor immune response
36. - regulatory cells that control intestinal inflammation
37. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
38. Costimulatory regulation of T cell function
39. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
40. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)A2 individuals